Fig. 2.

Butyrate supplementation enhances tumor susceptibility to ferroptosis in CRC mice. a, HCT116-bearing mice were administered butyrate, erastin, or both (n = 5/group). Tumor volume was monitored. b, Tumors were photographed and weighed at the experimental endpoint (Day 23). c, Tumor GSH levels were evaluated. d, Lipid peroxidation was evaluated by 4-HNE staining. e-g AOM/DSS-CRC mice were administered with butyrate, erastin, or both (n = 5/group). The size and number of tumor nodules were measured (e). (f) The levels of GSH in tumor tissues were evaluated. (g) The lipid peroxidation levels in tumor tissues were evaluated by 4-HNE staining. Data are represented as the mean ± SD. *p < 0.05; **p < 0.01; ***p < 0.001, two-tailed unpaired Student's t-test.